Can a Dual-Action antibody outsmart resistant tumors?

NCT ID NCT06028074

NEW Recruiting now Disease control Sponsor: Georgiamune Inc Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to find the safest dose and see if the drug can shrink tumors. It is the first time this drug is being given to humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GIM-122, an investigational dual-functioning monoclonal antibody given intravenously
What this could lead to: If successful, GIM-122 could offer a new treatment option for people with advanced solid tumors that have stopped responding to existing immunotherapies.
What could go wrong: This is an early-phase trial, so the drug may not be safe or effective. It is the first time GIM-122 is tested in humans, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID MALIGNANCIES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
NEXT Oncology Dallas
RECRUITING

Irving, Texas, 75039, United States
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40202, United States
Rutgers Cancer Institute of NJ
RECRUITING

New Brunswick, New Jersey, 08903, United States
Tennessee Oncology, PLLC
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology - Baylor Sammons Cancer Center
RECRUITING

Dallas, Texas, 75246, United States
The Angeles Clinic and Research Institute
RECRUITING

Los Angeles, California, 90025, United States
UCLA Hematology/Oncology
RECRUITING

Los Angeles, California, 90095, United States
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94143, United States
USC/Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.